Safety, Tolerability and Efficacy of ACTIMMUNE® Dose Escalation in Friedreich's Ataxia Study
Status:
Completed
Trial end date:
2017-03-21
Target enrollment:
Participant gender:
Summary
The purpose of this phase 3 multi-center, open-label extension study is to evaluate the
long-term safety of ACTIMMUNE® (interferon-γ 1b) in participants with Friedreich's Ataxia.